 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...5960616263646566676869...229230» |
- | Journal: Bisphenol F suppresses insulin-stimulated glucose metabolism in adipocytes by inhibiting IRS-1/PI3K/AKT pathway. (Pubmed Central) - Feb 9, 2022
Western blot analysis indicated that the activation of IRS-1/PI3K/AKT signaling pathway was inhibited by BPF, which resulted in reduced GLUT4 translocation. In conclusion, our data suggest that exposure of adipocytes to BPF may alter the expression of calorie metabolism-related adipokines and suppress insulin-stimulated glucose metabolism by impairing the insulin signaling (IRS-1/PI3K/AKT) pathway.
- | Journal: PDIA4 promotes glioblastoma progression via the PI3K/AKT/m-TOR pathway. (Pubmed Central) - Feb 9, 2022
Therefore, we believe that PDIA4 regulates the proliferation via activating the PI3K/AKT/m-TOR pathway and suppression of apoptosis in glioblastoma. It could be used as a potential target for the treatment of GBM.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, taselisib (GDC-0032) / Roche
Trial completion date, Combination therapy, Metastases: Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Feb 9, 2022
P1/2, N=30, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
It could be used as a potential target for the treatment of GBM. Trial completion date: Dec 2021 --> Jul 2022
- | sirolimus / Generic mfg.
Preclinical, Journal: Hydrogen-saturated saline mediated neuroprotection through autophagy via PI3K/AKT/mTOR pathway in early and medium stages of rotenone-induced Parkinson's disease rats. (Pubmed Central) - Feb 8, 2022
The results suggested that HS treatment exerted beneficial effects in early and medium stages before motor impairments emerged but not in the late stage of rotenone-induced PD rats. It exerted neuroprotection with RVLM catecholaminergic neurons and nigral dopamine neurons, mediated in part by decreasing levels of ROS and α-Syn through increasing autophagy machinery which were partly via inhibiting PI3K-Akt-mTOR pathway.
- | dexmedetomidine / Generic mfg.
Journal: The Protective Mechanism of Dexmedetomidine in Regulating Atg14L-Beclin1-Vps34 Complex Against Myocardial Ischemia-Reperfusion Injury. (Pubmed Central) - Feb 8, 2022
LY294002 attenuated the myocardial protective effect of DEX, indicating that Dex protected against cardiac I/R by activating the PI3K/Akt pathway. In conclusion, Dex upregulated the phosphorylation of Beclin1 at S295 site by activating the PI3K/Akt pathway and reduced the interactions of Atg14L-Beclin1-Vps34 complex, thus inhibiting autophagy and protecting against myocardial I/R injury.
- | sirolimus / Generic mfg.
Journal, IO biomarker: Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism. (Pubmed Central) - Feb 8, 2022
Finally, we provided evidence that inhibition of PI3K with pictilisib, AKT with perifosine, or mTOR with rapamycin, blocked the effects of IDO1 on protein synthesis and cardiomyocyte hypertrophy in Ang II-treated cells. Collectively, our findings identify that IDO1 promotes cardiomyocyte hypertrophy partially via PI3K-AKT-mTOR-S6K1 signaling.
- | LY294002 / Eli Lilly
Journal: Tumor-Suppressing STF cDNA 3 Overexpression Suppresses Renal Fibrosis by Alleviating Anoikis Resistance and Inhibiting the PI3K/Akt Pathway. (Pubmed Central) - Feb 8, 2022
Collectively, our findings identify that IDO1 promotes cardiomyocyte hypertrophy partially via PI3K-AKT-mTOR-S6K1 signaling. These findings provide a biological basis for further exploration of the therapeutic significance of targeting MF via TSSC3 in renal interstitial fibrosis.
- | apitolisib (GDC-0980) / Roche
Journal: Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation. (Pubmed Central) - Feb 8, 2022
The PI3K/mTORC2/HIF-2α/c-MYC axis may play a key role in this process. The PI3K inhibitor apitolisib may serve as a potential treatment option for patients suffering from HCC, especially in cases with rapidly growing tumors under mild chronic hypoxic conditions.
- | amiloride hydrochloride / Generic mfg.
Journal: Luteolin attenuates lipopolysaccharide-induced acute lung injury/acute respiratory distress syndrome by activating alveolar epithelial sodium channels via cGMP/PI3K pathway. (Pubmed Central) - Feb 8, 2022
The PI3K inhibitor apitolisib may serve as a potential treatment option for patients suffering from HCC, especially in cases with rapidly growing tumors under mild chronic hypoxic conditions. These results implied that Lut could attenuate pulmonary edema via enhancing the abundance of membrane ENaC at least partially through the cGMP/PI3K pathway, which could provide a promising therapeutic strategy for treating ALI/ARDS.
- | LY294002 / Eli Lilly
Journal: Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGFβR Regulating TGF-β/Smad Pathway. (Pubmed Central) - Feb 8, 2022
The effects of BBR were similar to those of the PI3K inhibitor LY294002 and TGF-β receptor inhibitor SB431542...Our experiments demonstrated BBR increased p-Smad2 and decreased p-Smad3 by binding to TGFβR1 and TGβFR2 inhibiting TGF-β/Smad, then, PI3K/AKT and other signaling pathways to restrain EMT, metastasis, and invasion in tumor cells. The effect of BBR was similar on the three tumor cells.
- | ZSTK474 / Zenyaku Kogyo
Journal: Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. (Pubmed Central) - Feb 8, 2022
Compounds 6r and 6s also demonstrated in vivo tolerability with therapeutic efficacy through reduction of kinase activation and amelioration of disease phenotypes in the JAK2V617F mutant myelofibrosis mouse cancer model. Taken together, these results support further structure optimization of 6r and 6s as promising leads for combination therapy in human cancer as a new class of PI3K/MEK bifunctional inhibitors.
- | imatinib / Generic mfg.
Journal: The Superior Cytotoxicity of Dual Targeting of BCR/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML. (Pubmed Central) - Feb 8, 2022
However, the ability of combinational therapy in diminishing K562 cell survival was potentiated either in the presence of 10058-F4 (c-Myc inhibitor) or Bortezomib (proteasome inhibitor), suggestive of the role of both NF-κB and c-Myc in overshadowing the therapeutic value of drugs combination. Taken together, the results of this study showed that inhibition of the PI3K pathway is a suitable approach to enhance the therapeutic value of imatinib in the treatment of CML.
- | erlotinib / Generic mfg.
Journal: FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway. (Pubmed Central) - Feb 8, 2022
Finally, FGFC1 effectively inhibited tumor growth in the nude mice xenograft model of NSCLC. Taken together, our results indicate that FGFC1 may be a potential candidate for erlotinib-resistant NSCLC therapy.
- || Ukoniq (umbralisib) / TG Therap
PK/PD data, Preclinical, Journal: Effect of Sophocarpine on the Pharmacokinetics of Umbralisib in Rat Plasma Using a Novel UPLC-MS/MS Method. (Pubmed Central) - Feb 8, 2022
This developed, optimized and technical UPLC-MS/MS method was extremely suitable for detecting the concentrations of umbralisib in rat plasma after an oral administration, and sophocarpine significantly changed the pharmacokinetics of umbralisib in rats. This obvious pharmacokinetic changes indicates that there seems to exist herb-drug interaction between sophocarpine and umbralisib.
- | Preclinical, Journal: Effects of chronic folate deficiency and sex differences on depression-like behavior in mice. (Pubmed Central) - Feb 8, 2022
Collectively, these results revealed that folate deficiency only led to depression-like behavior in female mice. This may be associated with reduced E2 levels, which may inhibit the PI3K/AKT pathway and upregulate the expression of cleaved caspase-3 to promote neuronal apoptosis.
- || Review, Journal, IO biomarker: Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. (Pubmed Central) - Feb 8, 2022
Thus far, clinical trials have yielded occasional successes intermixed with disappointments, reflecting significant hurdles which still remain including the complex crosstalk between oncogenic pathways and the nonlinear genetic development of myeloma, prone to cultivating sub-clones with distinctive mutations. In this review, we explore the landscape of precision therapeutics in multiple myeloma and underscore the degree to which research efforts have produced tangible clinical results.
- | Preclinical, Journal: Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency. (Pubmed Central) - Feb 5, 2022
Hyperuricemia-induced autophagy and NLRP3 dependent inflammation are critically involved in the development of renal damage. The inhibition of autophagy and inflammation are potential therapeutic strategies for uric acid nephropathy.
- | Journal: The Functional GRHL3-Filaggrin Axis Maintains a Tumour Differentiation Potential and Influences Drug Sensitivity. (Pubmed Central) - Feb 5, 2022
The loss of FLG in sensitive HNSCC resulted in a dramatic resistance to targeted therapies while the GRHL3-FLG signature predicted a favourable patient prognosis. This study provides evidence for a functional GRHL3-FLG tumour-specific differentiation axis that regulates targeted therapy response in HNSCC and establishes a rationale for clinical investigation of differentiation-paired targeted therapy in heterogeneous cancers.
- | Journal: Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways. (Pubmed Central) - Feb 5, 2022
These results indicated that Ang-(3-7) could alleviate cardiac remodeling. The administration of Ang-(3-7) attenuated hypertrophy of NRCMs via inhibiting the cAMP/PKA signaling pathway, and alleviated fibrosis of NRCFs via inhibiting PI3K/Akt signaling pathway.
- | dexmedetomidine / Generic mfg.
Journal: Dexmedetomidine protects the heart against ischemia reperfusion injury via regulation of the bradykinin receptors. (Pubmed Central) - Feb 5, 2022
The administration of Ang-(3-7) attenuated hypertrophy of NRCMs via inhibiting the cAMP/PKA signaling pathway, and alleviated fibrosis of NRCFs via inhibiting PI3K/Akt signaling pathway. DEX regulates BK receptor expression and potentiates the protection of BK in cardiac I/R injury, which suggests that modulating endogenous cardioprotective factors may play an important role in DEX-induced cardioprotection.
- | sirolimus / Generic mfg.
Preclinical, Journal, IO biomarker: Cardio-protective effect of tetrahydrocurcumin, the primary hydrogenated metabolite of curcumin in vivo and in vitro: Induction of apoptosis and autophagy via PI3K/AKT/mTOR pathways. (Pubmed Central) - Feb 5, 2022
In conclusion, THC effectively inhibited H/R-induced autophagy and apoptosis via, at least partially, activating the PI3K/AKT/mTOR pathways. THC might have the potential to be further developed into a potential candidate for the treatment of MI/R injury.
- | Preclinical, Journal: Increased expression of osteopontin in subchondral bone promotes bone turnover and remodeling, and accelerates the progression of OA in a mouse model. (Pubmed Central) - Feb 5, 2022
In addition, our results confirmed that inhibition of PI3K/AKT signaling pathway inhibits OPN-mediated OA subchondral bone remodeling and cartilage degeneration. This study revealed the role and mechanism of OPN in OA subchondral bone, which is of great significance for exploring specific biological indicators for early diagnosis of OA and monitoring disease progression, as well as for developing drugs to regulate the metabolism and turnover of subchondral bone and alleviate the subchondral bone sclerosis of OA.
- | Journal: MiR-137 inhibits cervical cancer progression via down-modulating Notch1 and inhibiting the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Feb 5, 2022
MiR-137 targets Notch1 and regulates CC through the PI3K/Akt/mTOR pathway. The miR-137/Notch1 axis may be a promising target for CC patients, and these findings can provide a reference for the clinical treatment of CC.
- | Preclinical, Journal, IO biomarker: Incaspitolide A extracted from Carpesium cernuum induces apoptosis in vitro via the PI3K/AKT pathway in benign prostatic hyperplasia. (Pubmed Central) - Feb 4, 2022
Further investigation revealed that treatment with TMJ-12 inhibited the PI3K/AKT pathway by increasing the expression of PTEN. Taken together, the results suggest that TMJ-12 prevents BPH-1 cell proliferation via the PI3K/AKT pathway by inducing apoptosis and cell cycle arrest.
- | Journal: Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation. (Pubmed Central) - Feb 4, 2022
When compared with the corresponding NC group, the number of cell clones in miR-202-5p mimic group and siRNA-PIK3CA group was decreased, and the invasion ability of miR-202-5p inhibitor group was increased, and the invasion ability was enhanced (all P 0.05). In conclusion, the overexpression of miR-202-5p can suppress PIK3CA gene expression and the activation of PI3K/Akt/mTOR signaling pathway to suppress the proliferation, invasion, and EMT of cervical cancer.
- | LY294002 / Eli Lilly
Journal: Activation of PI3K/PKB/GSK-3β signaling by sciadopitysin protects cardiomyocytes against high glucose-induced oxidative stress and apoptosis. (Pubmed Central) - Feb 4, 2022
Inhibition of PI3K/PKB/GSK-3β pathway by LY294002 blocked the effects of sciadopitysin on HG-induced injury, oxidative stress, and apoptosis in AC16 cells. Summarily, sciadopitysin alleviated HG-caused oxidative stress and apoptosis in cardiomyocytes by activating the PI3K/PKB/GSK-3β pathway.
- || Review, Journal: Traditional Chinese Medicine reverses resistance to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer: a narrative review. (Pubmed Central) - Feb 4, 2022
Many resistance mechanisms of EGFR-TKIs in the treatment of non-small cell lung cancer still need to be explored. CHMs have great research potential in reversing the resistance to EGFR-TKIs.
- | LY294002 / Eli Lilly, PD98059 / Wayne State University
Journal: An ApoA-I Mimic Peptide of 4F Promotes SDF-1α Expression in Endothelial Cells Through PI3K/Akt/ERK/HIF-1α Signaling Pathway. (Pubmed Central) - Feb 4, 2022
D-4F can upregulate the levels of HIF, p-Akt, and p-ERK in the abdominal aorta and inferior vena cava from mice. These results suggest that 4F promotes SDF-1α expression in ECs through PI3K/Akt/ERK/HIF-1α signaling pathway.
- | Byetta (exenatide) / AstraZeneca
Preclinical, Journal: Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy. (Pubmed Central) - Feb 3, 2022
Taken together, our results demonstrate that exendin-4 treatment relieved behavioral deficits, dopaminergic degeneration, and pathological α-synuclein aggregation in a parkinsonian rat model of α-synucleinopathy and that these effects were mediated by enhanced autophagy via inhibiting the PI3K/Akt/mTOR pathway. In light of the safety and tolerance of exendin-4 administration, our results suggest that exendin-4 may represent a promising disease-modifying treatment for Parkinson's disease.
- | ketamine / Generic mfg.
Journal: PI3K/AKT/mTOR and TLR4/MyD88/NF-κB Signaling Inhibitors Attenuate Pathological Mechanisms of Allergic Asthma. (Pubmed Central) - Feb 3, 2022
Torin2 had an effect on PU.1 expression. Inhibition of PI3K/AKT/mTOR and TLR4/MyD88/NF-κB signaling with targeted molecules can attenuate asthma pathology and play an important role in airways protection.
- | Preclinical, Journal: Electroacupuncture Pretreatment at Neiguan (PC6) attenuates autophagy in rats with myocardial ischemia reperfusion through the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway. (Pubmed Central) - Feb 3, 2022
Inhibition of PI3K/AKT/mTOR and TLR4/MyD88/NF-κB signaling with targeted molecules can attenuate asthma pathology and play an important role in airways protection. EA pretreatment promoted autophagy flux and alleviated myocardial I/R injury through the PI3K-Akt-mTOR pathway.
- | erlotinib / Generic mfg.
Journal, PARP Biomarker, IO biomarker: Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor. (Pubmed Central) - Feb 3, 2022
IHC results confirmed the WB results. These data imply that KAE may be a valid therapeutic candidate to potentiate PC cell sensitivity to ERL via inhibiting PI3K/AKT and EGFR signaling.
- || Review, Journal: Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article. (Pubmed Central) - Feb 3, 2022
AKT inhibitors may have significant adverse effects, but showed some evidence of improved survival. mTORC1 inhibitors show modest efficacy and significant adverse effects.
- | Journal: Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex. (Pubmed Central) - Feb 3, 2022
Both individuals experienced marked clinical improvement and notable reduction of keratoderma. In summary, a computational drug repositioning analysis successfully identified, to our knowledge, previously unreported targets in the treatment of EBS.
- | fasudil / Generic mfg.
Preclinical, Journal: Effect of Rho-Kinase and Autophagy on Remote Ischemic Conditioning-Induced Cardioprotection in Rat Myocardial Ischemia/Reperfusion Injury Model. (Pubmed Central) - Feb 3, 2022
Moreover, the rats in the RIC+fasudil+wortmannin group showed similar changes to those in the RIC+wortmannin group. These results showed that RIC protected the myocardium from I/R injury by suppressing Rho-kinase and the underlying mechanism may be related to enhancing autophagy via the PI3K/AKT pathway.
- Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Synergistic effects of Alpelisib (PI3K inhibitor) and Ribociclib (CDK 4/6 inhibitor) in preclinical colorectal cancer (CRC) models ([VIRTUAL]) - Feb 3, 2022 - Abstract #ESMOTAT2022ESMO_TAT_125;
A synergistic response to treatment with the combination of R+A is seen in all cell lines. We are currently investigating this combination in CRC animal models.
- | Journal: Inhibition of NF-κB might enhance the protective role of roflupram on SH-SY5Y cells under amyloid β stimulation via PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Feb 2, 2022
ROF treatment decreased expression of apoptosis-related molecules via inhibition of PI3K/AKT/mTOR signaling pathway, decreased expression of pro-inflammatory factors, and increased expression of key enzymes in the tricarboxylic acid (TCA) cycle was observed in SH-SY5Y cells after ROF treatment. Inhibition of NF-κB could enlarge these trends whereas overexpression of NF-κB could reduce these trends.
- | Journal: MiR-4787-5p regulates vascular smooth muscle cell apoptosis by targeting PKD1 and inhibiting the PI3K/Akt/FKHR pathway. (Pubmed Central) - Feb 2, 2022
Finally, it was found that miR-4787-5p deactivated the PI3K/Akt/FKHR pathway, as demonstrated by the down-regulation of phosphorylated (p-)PI3K, p-Akt, and p-FKHR. In conclusion, these findings confirm an important role for the miR-4787-5p/PKD1 axis in AD pathobiology.
- | Avastin (bevacizumab) / Roche
Journal, Combination therapy, BRCA Biomarker, PARP Biomarker: Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy. (Pubmed Central) - Feb 2, 2022
In general, PARP inhibitor and biological agent combinations are well tolerated, and early data suggest that they are clinically effective in both BRCA1/2 mutant and wild-type cancers. In this review, we discuss multiple clinical trials that are underway examining the antitumor activity of the most promising combination strategies.
- | everolimus / Generic mfg.
Preclinical, Journal: Everolimus inhibits PI3K/Akt/mTOR and NF-kB/IL-6 signaling and protects seizure-induced brain injury in rats. (Pubmed Central) - Feb 1, 2022
In this review, we discuss multiple clinical trials that are underway examining the antitumor activity of the most promising combination strategies. Everolimus can decrease the PI3K/Akt/mTOR and NF-kB/IL-6 signaling pathway, reduce neuronal apoptosis and microglia activation, and attenuate seizure susceptibility and intensity, thus having a protective effect on seizure-induced brain damage.
- | cisplatin / Generic mfg.
Journal: MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway. (Pubmed Central) - Feb 1, 2022
Besides, we found that miR-27a-3p added cisplatin sensitivity potentially through regulating PI3K/Akt signaling pathway. Taken together, MiR-27a-3p acted as a tumor suppressor gene in HCC cells, and it could be useful for modulating cisplatin sensitivity in chemotherapy therapy.
- | fimepinostat (CUDC-907) / Curis, Xospata (gilteritinib) / Astellas
Preclinical, Journal: The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. (Pubmed Central) - Feb 1, 2022
In addition, the combined treatment results in cooperative downregulation of cellular metabolites and persisting antileukemic effects. CUDC-907 plus gilteritinib shows synergistic antileukemic activity against FLT3-ITD AML in vitro and in vivo, demonstrating strong translational therapeutic potential.
- | ONX 0914 / Protalex
Journal: Inhibition of immunoproteasome subunit low molecular mass polypeptide 7 with ONX-0914 improves hypoxic-ischemic brain damage via PI3K/Akt signaling. (Pubmed Central) - Feb 1, 2022
Our findings indicate that LMP7 aggravates brain injury by triggering inflammatory responses in HIBD rats. LMP7 inhibition with ONX-0914 exerts protective effects on HIBD rats, possibly via PI3K/Akt signaling.
- | TriptoSar (triptolide) / Pierre Fabre
Journal: Effects of triptolide on radiosensitivity of human glioma cells and its mechanism. (Pubmed Central) - Feb 1, 2022
LMP7 inhibition with ONX-0914 exerts protective effects on HIBD rats, possibly via PI3K/Akt signaling. Triptolide could significantly increase the radiosensitivity of human glioma U251 cells and play a role by inhibiting the PI3K/Akt signal pathway.
- | Journal: NAD+ improved experimental autoimmune encephalomyelitis by regulating SIRT1 to inhibit PI3K/Akt/mTOR signaling pathway. (Pubmed Central) - Feb 1, 2022
Triptolide could significantly increase the radiosensitivity of human glioma U251 cells and play a role by inhibiting the PI3K/Akt signal pathway. NAD+ exerted a protective effect on EAE mice by inhibiting PI3K/Akt/mTOR signaling pathway through SIRT1 in TECs, and prevented EAE mice from sustained damage.
- | Journal: Hypoxia promotes steroidogenic competence of buffalo (Bubalus bubalis) theca cells. (Pubmed Central) - Feb 1, 2022
This study indicated that hypoxia enhanced the steroidogenic competence of buffalo TCs main through activating PI3K/AKT signaling pathway and subsequently facilitating the responsiveness of TCs to LH. This study provides a basis for further exploration of ovarian endocrine mechanism for steroidogenesis.
- | LY294002 / Eli Lilly
Journal: Neuroprotective Effect of Daidzein Extracted From Pueraria lobate Radix in a Stroke Model Via the Akt/mTOR/BDNF Channel. (Pubmed Central) - Feb 1, 2022
This protective effect of daidzein was ameliorated by inhibiting the PI3K/Akt/mTOR signaling pathway using LY294002. To sum up, our results demonstrated that daidzein could protect animals against ischemic damage through the regulation of the Akt/mTOR/BDNF channel, and the present study may facilitate the therapeutic research of stroke.
- ||| RLY-2608 / Relay Therap
New P1 trial, Combination therapy, Metastases: ReDiscover: First-in-Human Study of Mutant-selective PI3K? Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (clinicaltrials.gov) - Jan 30, 2022
P1, N=190, Recruiting, Sponsor: Relay Therapeutics, Inc.
- Identification of concurrent Wnt and PI3K activity as a potent driver of invasive cholangiocarcinoma ([VIRTUAL]) - Jan 30, 2022 - Abstract #LCS2022LCS_141;
Our study demonstrates that Nf2 is a rare driver gene of ICC that acts in a cooperative manner with oncogenic Kras to accelerate tumorigenesis. These tumours highlighted a concurrent Wnt and PI3K signaling signature, and we demonstrate that pharmacological coinhibition substantially impedes ICC growth, highlighting the use of Wnt and Pi3K inhibition as a broad treatment for ICC Patients.
- | temozolomide / Generic mfg.
Journal: Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway. (Pubmed Central) - Jan 29, 2022
Knockdown of circHIPK3 promoted TMZ sensitivity in glioma by modulating proliferation, metastasis, and apoptosis through miR-524-5p/KIF2A-mediated PI3K/AKT pathway. CircHIPK3 may be the potential target for the diagnosis and therapy of TMZ-resistant glioma.